Skip to Content

Vincristine Pregnancy and Breastfeeding Warnings

Vincristine is also known as: Oncovin, Vincasar PFS

Vincristine Pregnancy Warnings

Clinical reports of both male and female patients who received vincristine as a part of multiple agent chemotherapy indicate that azoospermia and amenorrhea can occur in postpubertal patients. Recovery occurred in some of the patients many months after the chemotherapy had been completed. In studies of several animal species, the drug has induced teratogenesis or embryonic fatality at dosages which were nontoxic to the pregnant animals.

Vincristine has been assigned to pregnancy category D by the FDA. Animal studies have revealed evidence of teratogenicity. When administered as a part of combination antineoplastic therapy, vincristine may produce gonadal dysfunction in men and women. There are no controlled data in human pregnancy. Vincristine should only be given during pregnancy when there are no alternatives and benefit outweighs risk. If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, she should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving this medication.

See references

Vincristine Breastfeeding Warnings

There are no data on the excretion of vincristine into human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions to vincristine in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Oncovin (vincristine)." Lilly, Eli and Company, Indianapolis, IN.
  2. Lishner M, Zemlickis D, Degendorfer P, Panzarella T, Sutcliffe SB, Koren G "Maternal and foetal outcome following Hodgkin's disease in pregnancy." Br J Cancer 65 (1992): 114-7
  3. Martin RH, Rademaker AW, Leonard NJ "Analysis of chromosomal abnormalities in human sperm after chemotherapy by karyotyping and fluorescence in situ hybridization (FISH)." Cancer Genet Cytogenet 80 (1995): 29-32
  4. Andrieu JM, Ochoa-Molina ME "Menstrual cycle, pregnancies and offspring before and after MOPP therapy for Hodgkin's disease." Cancer 52 (1983): 435-8
  5. Aviles A, Diaz-Maqueo JC, Talavera A, Guzman R, Garcia EL "Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children." Am J Hematol 36 (1991): 243-8
  6. Radford JA, Clark S, Crowther D, Shalet SM "Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma." Br J Cancer 69 (1994): 379-81
  7. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 5th ed." Baltimore, MD: Williams & Wilkins (1998):
  8. Brandriff BF, Meistrich ML, Gordon LA, Carrano AV, Liang JC "Chromosomal damage in sperm of patients surviving Hodgkin's disease following MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone) therapy with and without radiotherapy." Hum Genet 93 (1994): 295-9
  9. Jones RT, Weinerman BH "MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone) given during pregnancy." Obstet Gynecol 54 (1979): 477-8
  10. Johnson SA, Goldman JM, Hawkins DF "Pregnancy after chemotherapy for Hodgkin's disease." Lancet 2 (1979): 93

References for breastfeeding information

  1. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 5th ed." Baltimore, MD: Williams & Wilkins (1998):
  2. "Product Information. Oncovin (vincristine)." Lilly, Eli and Company, Indianapolis, IN.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.